Transgene news
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that an abstract reporting preliminary data from the two Phase I trials assessing TG4050, its individualized neoantigen cancer vaccine, has been selected for a poster presentation at the American Society of Clinical Oncology (ASCO) annual meeting. The conference will be held online and in-person in Chicago, IL, USA, from June 3 to 7, 2022.
The
The Combined Ordinary and Extraordinary General Meeting of Transgene’s shareholders was held today (May 25, 2022) at 10:00 a.m. at the Company’s headquarters (400 boulevard Gonthier d’Andernach – Parc d’Innovation – 67400 Illkirch-Graffenstaden, France).
The meeting was chaired by Hedi Ben Brahim, CEO, to approve the Company’s financial statements for the year ended December 31, 2021, and to vote on the other resolutions submitted for approval
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy:
- Relevant neoantigens could be identified in all evaluable patients and TG4050 induced tumor specific T cell responses against multiple of these patient-specific neoantigen targets.
- Early signs of clinical activity were observed with encouraging ongoing anti-tumor activity in the first patients under neoantigen vacc
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shareholders is available.
The notice of meeting, comprising the agenda and the draft resolutions was published in the Bulletin des Annonces Légales Obligatoires (BALO) n° 39 of April 1 st, 2022.
These notices include informat
- The roles of Chairman and Chief Executive Officer will be separated.Dr. Riva proposed as new independent Director and non-executive Chairman of the Board.
- With more than 30 years of experience in the industry, Dr. Riva will work with Transgene’s CEO Hedi Ben Brahim to realize the potential of the Company’s technology platforms and products to benefit cancer patients.
- Transgene’s Board of Directors also proposes the appointment of Prof. Jean-Yves Bl